Neuromodulation to Facilitate the Effect of Ketamine (TMS/ketamine)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
The Neuroscience Center, LLC
ClinicalTrials.gov Identifier:
NCT01816958
First received: March 11, 2013
Last updated: March 20, 2013
Last verified: March 2013
  Purpose
application of external neuromodulation along with ketamine infusion.

Condition Intervention
Depression
Chronic Pain
Substance Abuse
Other: co-administration of TMS and infused ketamine

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Treatment of Thalamocortical Dysrhythmia Using External Neuromodulation to Facilitate the Therapeutic Effect of Ketamine.

Resource links provided by NLM:


Further study details as provided by The Neuroscience Center, LLC:

Primary Outcome Measures:
  • Global Assessment of Function in DSM-4R [ Time Frame: up to 3 years ] [ Designated as safety issue: No ]
    treat in order to cause remission of disability


Enrollment: 35
Study Start Date: January 2011
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
chronic depression and/or pain
co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
Other: co-administration of TMS and infused ketamine
co-administration of TMS and infused ketamine

Detailed Description:
apply TMS concurrent with ketamine infusion in order to increase the likliehood & strength of therapeutic benefit
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients within my own clinic, suffering with chronic emotional and/or somatic pain
Criteria

Inclusion Criteria:

  • chronically ill,
  • treatment-resistant

Exclusion Criteria:

  • active psychosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01816958

Locations
United States, Illinois
The Neuroscience Center
Deerfield, Illinois, United States, 60015
Sponsors and Collaborators
The Neuroscience Center, LLC
Investigators
Principal Investigator: Steven R Devore Best, M.D. The Neuroscience Center
  More Information

Responsible Party: The Neuroscience Center, LLC
ClinicalTrials.gov Identifier: NCT01816958     History of Changes
Other Study ID Numbers: 12_1293 
Study First Received: March 11, 2013
Last Updated: March 20, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by The Neuroscience Center, LLC:
thalamocortical dysrhythmia
transcranial magnetic stimulation (TMS)
transcranial Electrical Stimulation (tES)
(N-methyl-D-aspartate) NMDA-R antagonist
ketamine infusion
neuromodulation
synergistic effect
remission

Additional relevant MeSH terms:
Chronic Pain
Substance-Related Disorders
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Chemically-Induced Disorders
Mental Disorders
Ketamine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 28, 2016